Answer

IFF Scent recovery: drivers, H2 evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan aimed at 2027

1) Drivers of Scent’s recovery

Scent (in IFF’s reporting) is recovering through a combination of (a) stronger performance in Fragrance Ingredients, (b) stabilization/recovery in Fine Fragrance despite Middle East volatility, and (c) R&D and go-to-market rebuilding in Consumer Fragrance.

A. Fragrance Ingredients: strong Q2 momentum, then normalization to higher-value mix

In Q2 2026, Scent sales grew 8%, and a key driver was Fragrance Ingredients growth “north of 20%.” ¹
Management attributes part of the strength to the prior-year comparison (“comparing to a down 10% or more in the year ago period”) and part to execution: leveraging the synthetics portfolio to capture sales amid macro/supply-chain pressure and higher Brent crude prices. ¹
For the recovery path, management explicitly expects normalization: Fragrance Ingredients growth will shift “towards the higher value-added ingredients versus the traditional synthetics,” with the team positioning the business for stronger competitive position “as we go into next year and the year after.” ²

B. Fine Fragrance: operational management of Middle East uncertainty, with a weaker Q3 and stronger Q4 profile

Fine Fragrance faced Middle East-related noise, but management says it “managed the challenges” such that the business finished “up slightly positive” even though it had expected Fine Fragrance growth to be down “mid-single digits” entering the quarter. ¹
For Scent’s second-half recovery shape, management expects Fine Fragrance to be “a little bit softer in Q3, but a stronger Q4,” targeting a mid-single-digit second-half growth rate. ²
The Middle East dynamic also shows up in the difficulty of the comps: Q3 last year had 20% growth, so even if the market is volatile, the trajectory is “trending in the right direction” as recovery comes into Q4. ¹

C. Consumer Fragrance: market-share rebuilding supported by R&D capability recovery

On the Consumer Fragrance side, management frames recovery as tied to rebuilding R&D capability and a go-to-market approach with customers, aiming to drive market share gains. ²
In the second half, Consumer Fragrance is expected to be in the “low single-digit range,” with Q2 already strong (management notes Q2 was “high single-digit” and should “normalize” going forward). ²
In Q2, Consumer Fragrance execution is confirmed by results: overall Scent sales were up 8%, with Consumer Fragrance described as “high single-digit increase” and Fine Fragrance “low single digits” in the segment performance summary. ³

D. R&D pipeline and capability: progress over ~2.5 years, now transitioning into execution/innovation scale

Management highlights that 2.5 years ago the R&D pipeline “was not what it should have been” and that today the company believes it has a “very strong R&D capability,” including “a great pipeline of molecules as well as delivery systems.” ⁴
The R&D effort is also described as strengthened on both Fine Fragrance and Consumer Fragrance, with “perfumers” developing “leading-edge new Fine Fragrances and Consumer Fragrances.” ⁴

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (2026)

Management gave a directional bridge for H2 that distinguishes between Fine Fragrance and Consumer Fragrance.

Fine Fragrance (H2): mid-single-digit growth, softer Q3 then stronger Q4

Expectation: Fine Fragrance is “a little bit softer in Q3, but a stronger Q4,” implying mid-single-digit growth for the second half on a general basis. ²
Underlying reason: Middle East uncertainty continues and the company is “factoring in a softer Q3,” while still guided toward “recovery as we get to Q4 overall.” ¹

Consumer Fragrance (H2): low single-digit growth, normalization after a strong Q2

Expectation: Consumer Fragrance is expected to be “in that low single-digit range” for H2, with normalization from the “really good Q2 at a high single-digit number.” ²
R&D/go-to-market role: management links the outlook to “rebuild the R&D capability go-to-market approach with customers” to pursue market share gains. ²

Fragrance Ingredients (context that matters for Scent recovery): normalization pressure on yoy

While your question is specifically Fine Fragrance vs Consumer Fragrance, the Scent recovery also depends on Fragrance Ingredients. Management states Fragrance Ingredients “will normalize” and is “slightly under pressure in terms of year-over-year performance” as synthetics tailwinds ease. ²

3) Plan for R&D to support 2027

The excerpts describe an R&D “capability rebuild” that is now translating into pipeline depth and competitive positioning by 2027, but they do not provide a detailed, line-item budget or explicit 2027 milestones. What is clear is (a) capability has been rebuilt over ~2.5 years, (b) the company has a strengthened pipeline, and (c) management expects competitive strength to improve beyond the current year.

A. R&D capability rebuild: pipeline quality, delivery systems, and leading-edge perfumery

The R&D pipeline is described as materially improved versus “2.5 years ago,” moving to “a very strong R&D capability.” ⁴
Management specifically calls out “a great pipeline of molecules as well as delivery systems,” and highlights perfumers developing “leading-edge new Fine Fragrances and Consumer Fragrances.” ⁴
They also emphasize ongoing work: management is “not satisfied” and says there is “a lot more to do,” even while being optimistic. ⁴

B. Competitive positioning by “next year and the year after” (i.e., beyond 2026), supported by innovation focus

For Fragrance Ingredients, management states the strategic shift to “higher-value natural products” is underway and will take “a little bit more time” but, crucially, they believe that as they go into “next year and the year after,” they will have a “really strong competitive position.” ²
While that sentence explicitly names Fragrance Ingredients, it is consistent with the overall theme of R&D-driven capability building leading into subsequent years (including 2027). ²⁴

C. How the company positions R&D as part of market-share recovery (especially Consumer Fragrance)

For Consumer Fragrance specifically, the company ties progress to rebuilding the R&D capability and the go-to-market approach with customers to “drive market share gains.” ²
That implies that the 2027 support plan is not just molecule discovery—it includes commercialization readiness (customer-facing execution) so innovation can translate into share. ²

D. Broader “innovation matters” framework for the Remainco portfolio

IFF also frames innovation as a strategic loop that requires continued reinvestment: “percentage of sales in terms of R&D… is… in that 8% to 9% range,” and “innovation matters” because investments lead to better growth and margin, then enable further reinvestment. ⁵
This supports the idea that R&D in 2027 is planned as an ongoing, funded capability rather than a one-time reset. ⁵

Bottom line

Drivers of recovery: Scent’s rebound is driven by strong Fragrance Ingredients performance in the near term (then normalization to higher-value mix), careful Fine Fragrance management through Middle East uncertainty (softer Q3, stronger Q4), and Consumer Fragrance recovery supported by rebuilt R&D capability and go-to-market execution aimed at market share gains. ²¹
Second half evolution (2026): Fine Fragrance is guided to mid-single-digit H2 growth with Q3 softer / Q4 stronger; Consumer Fragrance is expected to normalize to low single-digit after Q2’s high-single-digit strength. ²
R&D plan to support 2027: Management highlights a completed “capability rebuild” over ~2.5 years (strong pipeline of molecules + delivery systems; leading-edge perfumery output), with ongoing work to close gaps, and an innovation-to-competitive-positioning trajectory extending into “next year and the year after” (supporting 2027). ⁴²

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Driven by Fragrance Ingredients; H2 Outlook and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery: drivers, H2 evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan aimed at 2027

1) Drivers of Scent’s recovery

A. Fragrance Ingredients: strong Q2 momentum, then normalization to higher-value mix

B. Fine Fragrance: operational management of Middle East uncertainty, with a weaker Q3 and stronger Q4 profile

C. Consumer Fragrance: market-share rebuilding supported by R&D capability recovery

D. R&D pipeline and capability: progress over ~2.5 years, now transitioning into execution/innovation scale

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (2026)

Fine Fragrance (H2): mid-single-digit growth, softer Q3 then stronger Q4

Consumer Fragrance (H2): low single-digit growth, normalization after a strong Q2

Fragrance Ingredients (context that matters for Scent recovery): normalization pressure on yoy

3) Plan for R&D to support 2027

A. R&D capability rebuild: pipeline quality, delivery systems, and leading-edge perfumery

B. Competitive positioning by “next year and the year after” (i.e., beyond 2026), supported by innovation focus

C. How the company positions R&D as part of market-share recovery (especially Consumer Fragrance)

D. Broader “innovation matters” framework for the Remainco portfolio

Bottom line

References

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook

IFF's Scent Recovery Fueled by 2026 Q2 R&D Reboot; H2 Outlook and 2027 Plan

IFF’s Scent Recovery Driven by Fragrance Ingredients, R&D Push Toward 2027 in Q2 2026

IFF Scent Recovery Driven by Fragrance Ingredients, 2H 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Fragrance Ingredients, Q2 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Strengthens as Q2 2026 Highlights R&D Path to 2027

IFF Scent Recovery Gains Traction in Q2 2026, R&D Plan Sets 2027 Outlook

IFF Scent Recovery Gains Momentum in 2H, R&D Plan Targets 2027

IFF's Scent Recovery Fueled by Fragrance Ingredients Momentum and 2027 R&D Plan

IFF Q2 2026 Highlights on Scent Recovery, H2 Fragrance Outlook, and 2027 R&D Plan